FibroBiologics (FBLG) Corporate presentation summary

Strategic vision and technology platform

• Focuses on harnessing fibroblasts for immune modulation and regenerative therapies targeting chronic diseases.

• Fibroblasts are highlighted as abundant, underutilized cells with roles in tissue repair, immune regulation, and regeneration.

• Platform leverages allogeneic fibroblasts, enabling scalable, low-cost manufacturing and broad disease applicability.

• Over 270 issued or pending patents support a robust intellectual property position.

• Addresses a $4 trillion chronic disease market with potential for diversified, durable revenue.

Clinical and preclinical pipeline

• Active Phase 1/2 clinical trial for diabetic foot ulcers; IND submitted for psoriasis trial.

• Pipeline includes candidates for wound healing, autoimmune diseases, tissue regeneration, oncology, and diabetes.

• CYWC628 demonstrated superior wound closure rates in animal models versus FDA-approved comparators.

• CYPS317 showed significant reduction in psoriasis severity and pro-inflammatory cytokines in preclinical models.

• Additional research in multiple sclerosis, degenerative disc disease, human longevity, and cancer immunotherapy.

Market need and competitive positioning

• Chronic diseases affect 60% of Americans and drive 90% of healthcare costs.

• Diabetic foot ulcers and psoriasis represent high unmet needs with limited durable therapies.

• CYPS317 offers multi-cytokine modulation, immune restoration, and scalable manufacturing, differentiating it from current biologics.

• Fibroblast therapies aim for disease modification and durable remission, not just symptom management.